Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers
العنوان: | Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers |
---|---|
المؤلفون: | Hervé Tiriac, Heather M. Sonnemann, Ivy Lai, Jason Roszik, Christopher A. Bristow, Minying Zhang, David A. Tuveson, Patrick Hwu, Robert A. Wolff, Fenge Li, Brenda Melendez, Christine B. Peterson, Bih Fang Pan, Arjun S. Katailiha, Michael P. Kim, Cassian Yee, Amjad H. Talukder, Philip L. Lorenzi, Yulun Chiu, Anirban Maitra, Milind Javle, Scott Kopetz, Mark W. Hurd, Na Qiao, David H. Hawke, Gregory Lizée, Rebecca Davis, Elizabeth A. Mittendorf, Kyle R. Jackson, Sherille D. Bradley, Ya'an Kang, Héctor M. Alvarez |
المصدر: | Nature Communications, Vol 11, Iss 1, Pp 1-12 (2020) Nature Communications |
بيانات النشر: | Nature Portfolio, 2020. |
سنة النشر: | 2020 |
مصطلحات موضوعية: | Cytotoxicity, Immunologic, 0301 basic medicine, Placenta, medicine.medical_treatment, General Physics and Astronomy, Cancer immunotherapy, Immunotherapy, Adoptive, 0302 clinical medicine, Pregnancy, Cytotoxic T cell, lcsh:Science, HLA-A1 Antigen, Cancer, Multidisciplinary, Prognosis, DNA-Binding Proteins, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Female, Carcinoma, Pancreatic Ductal, Biotechnology, T cell, Science, Immunology, Breast Neoplasms, Article, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, Targeted therapies, Breast cancer, Antigen, Antigens, Neoplasm, Cell Line, Tumor, Pancreatic cancer, Biomarkers, Tumor, medicine, Humans, business.industry, Gene Expression Profiling, General Chemistry, Immunotherapy, medicine.disease, digestive system diseases, Pancreatic Neoplasms, CTL, 030104 developmental biology, Cancer research, lcsh:Q, business, T-Lymphocytes, Cytotoxic, Transcription Factors |
الوصف: | Cytotoxic T lymphocyte (CTL)-based cancer immunotherapies have shown great promise for inducing clinical regressions by targeting tumor-associated antigens (TAA). To expand the TAA landscape of pancreatic ductal adenocarcinoma (PDAC), we performed tandem mass spectrometry analysis of HLA class I-bound peptides from 35 PDAC patient tumors. This identified a shared HLA-A*0101 restricted peptide derived from co-transcriptional activator Vestigial-like 1 (VGLL1) as a putative TAA demonstrating overexpression in multiple tumor types and low or absent expression in essential normal tissues. Here we show that VGLL1-specific CTLs expanded from the blood of a PDAC patient could recognize and kill in an antigen-specific manner a majority of HLA-A*0101 allogeneic tumor cell lines derived not only from PDAC, but also bladder, ovarian, gastric, lung, and basal-like breast cancers. Gene expression profiling reveals VGLL1 as a member of a unique group of cancer-placenta antigens (CPA) that may constitute immunotherapeutic targets for patients with multiple cancer types. Cytotoxic T lymphocyte (CTL)-based immunotherapies can induce tumor regressions by targeting HLA class I-bound tumor-associated peptides. Here, the authors identified a peptide derived from Vestigial-like 1 (VGLL1) as a shared, potentially therapeutic CTL target expressed by multiple cancer types. |
اللغة: | English |
تدمد: | 2041-1723 |
URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5564e046151f65f17a494f8f54632afd https://doaj.org/article/edce20ec2f5b48fd83a56ffb4325c6fb |
حقوق: | OPEN |
رقم الأكسشن: | edsair.doi.dedup.....5564e046151f65f17a494f8f54632afd |
قاعدة البيانات: | OpenAIRE |
تدمد: | 20411723 |
---|